Page 1868 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 125

REFERENCES

1. Bodenham A, Shelly MP, Park GR. The altered pharmacokinet- 15. Weinshilboum R. Genomic medicine: inheritance and drug
ics and pharmacodynamics of drugs commonly used in criti- response. N Engl J Med. 2003;348:529.
cally ill patients. Clin Pharmacokinet. 1988;14:347. 16. Wang L, McLeod H, Weinshilboum R. Genomics and drug
2. Nightingale CH, Carver P. Basic principles of pharmacokinetics. response. N Engl J Med. 2011;364:1144-1153.
Clin Lab Med. 1987;7:267. 17. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for
3. Winter ME. Basic principles. In: Koda-Kimble MA, Young LY, hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
eds. Basic Clinical Pharmacokinetics. 3rd ed. Vancouver, WA: 18. National Institute of Health Pharmacogenetics Research
Applied Therapeutics; 1994:12. Network’s PharmGKB: The Pharmacogenetics and the
4. Rowland M, Tozer TN. Clinical Pharamcokinetics: Concepts Pharmacogenomics Knowledge Base. www.pharmgkb.org.
and Applications. 3rd ed. Philadelphia, PA: Lea and Febiger, Accessed November 9, 2014.
1995:35. 19. Perazella MA. Drug use and nephrotoxicity in the intensive care
5. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the unit. Kidney Int. 81:1172-1178.
dynamics of drug absorption, distribution, and elimination. 20. Matzke GR, Aronoff GR, Atkinson AJ et al. Drug dosing consid-
In: Hard-man JG, Gilman AG, Limbird LI, eds. Goodman & eration in patients with acute and chronic kidney disease-a clin-
Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. ical update from Kidney Disease: Improving Global Outcomes
New York: McGraw-Hill; 1996:3. (KDIGO). Kidney Int. 2011;80:1122-1137.
6. Pratt WB. The entry, distribution, and elimination of drugs. 21. Murray P, Wylam ME. Dopamine, dobutamine, and dopexamine.
In: Pratt WB, Taylor P, eds. Principles of Drug Action. 3rd ed. In: Leff AR, ed. Pulmonary and Critical Care Pharmacology and
New York: Churchill Livingstone; 1990:231-236. Therapeutics. New York: McGraw-Hill; 1996:239-250.
7. Neubig RR. The time course of drug action. In: Pratt WB, 22. Martin SJ, Danziger LH. Continuous infusion of loop diuret-
Taylor P, eds. Principles of Drug Action. 3rd ed. New York: ics in the critically ill: a review of the literature. Crit Care Med.
Churchill Livingstone; 1990:48. 1994;22:1323.
8. Pond SM, Tozer TN. First-pass elimination: basic concepts and 23. Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics in
clinical consequences. Clin Pharmacokinet. 1984;9:1. chronic renal insufficiency: a continuous infusion is more effi-
9. Gibaldi M, Koup JR. Pharmacokinetic concepts—drug bind- cacious than bolus therapy. Ann Intern Med. 1991;115:360.
ing, apparent volume of distribution and clearance. Eur J Clin 24. Kress JP, O’Connor MF, Pohlman AS, et al. Sedation of critically
Pharmacol. 1981;20:299. ill patients during mechanical ventilation: a comparison of pro-
10. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling pofol and midazolam. Am J Respir Crit Care Med. 1996;153:1012.
of pharmacokinetics and pharmacodynamics: application to 25. Pohlman AS, Simpson KP, Hall JB. Continuous intravenous
dtubocurarine. Clin Pharmacol Ther. 1979;25:358. infusions of lorazepam versus midazolam for sedation during
11. Stargel WW, Shand DG, Routledge PA, et al. Clinical com- mechanical ventilatory support: a prospective, randomized
parison of rapid infusion and multiple injection methods for study. Crit Care Med. 1994;22:1241.
lidocaine loading. Am Heart J. 1991;102:872. 26. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interrup-
12. Reidenberg MM, Levy M, Warner H, et al. Relationship tion of sedative infusions in critically ill patients undergoing
between diazepam dose, plasma level, age, and central nervous mechanical ventilation. N Engl J Med. 2000;342:1471.
system depression. Clin Pharmacol Ther. 1978;23:371. 27. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of
13. Zhou H-H, Koshakji RP, Silberstein DJ, et al. Racial differences creatinine as a filtration marker in glomerulopathic patients.
in drug response: altered sensitivity to and clearance of pro- Kidney Int. 1985;28:830.
panolol in men of Chinese descent as compared to American 28. Rabito CA, Panico F, Rubin R, et al. Noninvasive, real-time
whites. N Engl J Med. 1989;320:565. monitoring of renal function during critical care. J Am Soc
14. Lang CC, Stein CM, Brown RM, et al. Attenuation of Nephrol. 1994;4:1421.
isoproterenol-mediated vasodilatation in blacks. N Engl J Med. 29. Cockroft DW, Gault MH. Prediction of creatinine clearance
1995;333:155. from serum creatinine. Nephron. 1976;16:31.

Section11-O-Ref.indd 1 12/10/2014 8:08:26 PM